- Previous Close
878.29 - Open
872.50 - Bid 846.16 x 1100
- Ask 864.30 x 1100
- Day's Range
854.27 - 877.90 - 52 Week Range
446.89 - 966.10 - Volume
2,654,240 - Avg. Volume
2,867,990 - Market Cap (intraday)
774.24B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
126.64 - EPS (TTM)
6.79 - Earnings Date Aug 8, 2024
- Forward Dividend & Yield 5.20 (0.60%)
- Ex-Dividend Date Aug 15, 2024
- 1y Target Est
917.64
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
www.lilly.com43,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: LLY
View MoreRelated Videos: LLY
Performance Overview: LLY
Trailing total returns as of 7/24/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LLY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LLY
View MoreValuation Measures
Market Cap
790.82B
Enterprise Value
814.44B
Trailing P/E
129.35
Forward P/E
64.10
PEG Ratio (5yr expected)
1.42
Price/Sales (ttm)
22.08
Price/Book (mrq)
61.72
Enterprise Value/Revenue
22.67
Enterprise Value/EBITDA
84.06
Financial Highlights
Profitability and Income Statement
Profit Margin
17.08%
Return on Assets (ttm)
12.60%
Return on Equity (ttm)
50.75%
Revenue (ttm)
35.93B
Net Income Avi to Common (ttm)
6.14B
Diluted EPS (ttm)
6.79
Balance Sheet and Cash Flow
Total Cash (mrq)
2.65B
Total Debt/Equity (mrq)
204.28%
Levered Free Cash Flow (ttm)
-1.23B
Research Analysis: LLY
View MoreCompany Insights: LLY
LLY does not have Company Insights
Research Reports: LLY
View MoreDaily – Vickers Top Buyers & Sellers for 07/12/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 07/10/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 07/09/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Eli Lilly: Announced Morphic Acquisition Yields Potential New Blockbuster Inflammatory Bowel Drug
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
RatingPrice Target